Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 8/20 | 0.60 |
| ▸ | METAP1 | P53582 | 4/20 | 0.60 |
| ▸ | CNR1 | P21554 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.51 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.51 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.51 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.51 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3529974 | 0.80 | HPGD (0.67) | METAP2METAP1CNR1HPGDALDH1A1 | |
| SCHEMBL4038474 | 0.78 | HPGD (0.69) | CNR1HPGDALDH1A1PLAAT3PLAAT5 | |
| SCHEMBL1952759 | 0.78 | LMNA (0.63) | CNR1ALDH1A1KMT2A | |
| SCHEMBL3644597 | 0.78 | METAP2 (0.50) | METAP2METAP1CNR1HPGDMAPK1 | |
| SCHEMBL3644595 | 0.78 | METAP2 (0.50) | METAP2METAP1CNR1HPGDMAPK1 | |
| SCHEMBL18251703 | 0.78 | KDM4E (0.55) | METAP2METAP1CNR1HPGDKMT2A | |
| SCHEMBL13034051 | 0.75 | CNR1 (0.57) | METAP2METAP1CNR1HPGDMAPK1 | |
| SCHEMBL18887747 | 0.75 | LMNA (0.57) | MAPK1ALDH1A1KMT2A | |
| SCHEMBL6435988 | 0.75 | TRPV1 (0.60) | METAP2CNR1HPGDALDH1A1PLAAT3 | |
| SCHEMBL14438295 | 0.74 | MEN1 (0.57) | METAP2METAP1CNR1HPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130172322-A1 | BENZAZEPINE DERIVATIVES USEFUL FOR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | ARENA PHARMACEUTICALS, INC. | 2013-07-04 | — | — | US | disclosed |
| US-8404675-B2 | Benzazepine derivatives and methods of prophylaxis or treatment of 5HT2C receptor associated diseases | ARENA PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20100173894-A1 | BENZAZEPINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | ARENA PHARMACEUTICALS, INC. | 2010-07-08 | — | — | US | disclosed |
| US-7704993-B2 | Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases | ARENA PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20070142357-A1 | Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases | ARENA PHARMACEUTICALS, INC. | 2007-06-21 | — | — | US | disclosed |
| EP-1633720-A1 | BENZAZEPINE DERIVATIVES USEFUL FOR THE TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | Arena Pharmaceuticals, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2005003096-A1 | BENZAZEPINE DERIVATIVES USEFUL FOR THE TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | ARENA PHARMACEUTICALS, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173894-A1 | BENZAZEPINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | HTR2C, TPH2, HTR2A | METAP2 674/4885METAP1 1277/4885CNR1 51/4885 |
| US-20130172322-A1 | BENZAZEPINE DERIVATIVES USEFUL FOR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | HTR2C, HTR2A, TPH2 | METAP2 644/4885METAP1 1261/4885CNR1 60/4885 |
| US-20070142357-A1 | Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases | HTR2C, TPH2, HTR2A | METAP2 674/4885METAP1 1277/4885CNR1 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.